U.S. Food and Drug Administration (FDA) · United States
FDA MoCRA Cosmetics Modernization — Marketing Claims
Cosmetic marketing must stay within cosmetic (appearance) claims, must not imply FDA approval, and cosmetic labels must include MoCRA adverse-event contact information.
What is FDA MoCRA Cosmetics Modernization — Marketing Claims?
Cosmetic marketing must stay within cosmetic (appearance) claims, must not imply FDA approval, and cosmetic labels must include MoCRA adverse-event contact information. Cosmetic product ads, influencer posts, websites and labels. This guide summarizes the supplied rule information for marketing review. Use the linked official source to confirm the current text, applicability and any exceptions before making a compliance decision. Confirm
Cosmetic marketing must stay within cosmetic (appearance) claims, must not imply FDA approval, and cosmetic labels must include MoCRA adverse-event contact information.
How can marketing teams comply?
Cosmetic product ads, influencer posts, websites and labels.
What is FDA MoCRA Cosmetics Modernization — Marketing Claims?
Cosmetic marketing must stay within cosmetic (appearance) claims, must not imply FDA approval, and cosmetic labels must include MoCRA adverse-event contact information.
Supplements, cosmetics, foods and CBD products become unapproved drugs if their marketing claims to diagnose, treat, cure, mitigate or prevent disease, and cosmetics also may not claim to affect body structure or function.
OTC external drug products covered by 21 CFR 358 (warts, corns and calluses, ingrown toenails, lice, dandruff, seborrheic dermatitis, psoriasis) may only claim the uses and actives in their monograph.
Food and supplement labels may link a substance to reduced disease risk only through FDA-authorized or qualified health claims, in the required form, and only on foods meeting nutrient eligibility; disease treatment claims are not allowed.
Infant formula and baby food marketing must not be misleading, including claims of equivalence to breast milk, disease prevention, guaranteed development or absolute contaminant-free status; formulas must meet FDA nutrient and notification requirements.
Firm communications sharing scientific information on unapproved uses with HCPs must follow FDA's January 2025 final SIUU guidance: scientifically sound sources, required disclosures, no persuasive elements, and separation from promotion.
Prescription drug promotion must stay within the approved indication; information on unapproved uses may be shared only separately from promotion under FDA's safe-harbor guidance or in reply to unsolicited requests.
Request a free compliance scan of your homepage and book a time with Warrant.